2. Methodology and Inclusion Criteria

The tracker only includes platforms where at least one of the following primary-source artifacts could be verified in 2024, 2025, or first half of 2026: a sponsor portfolio page listing the platform, a SEC filing referencing the platform, a named press release on the platform’s website or the sponsor’s website, a PitchBook profile with a transaction date, or a verifiable trade press article citing a named buyer and seller. Where a sponsor name appeared only in older secondary press without confirmation in a sponsor portfolio page or a transaction document, the attribution is moved to Section 19 Gap Disclosures and flagged as unverified. This is the same gating that the CT Acquisitions team applied to the home-health, behavioral health, ABA, veterinary, dermatology, dental DSO, physical therapy, ophthalmology, gastroenterology, and orthopedic trackers in this sibling series.

Confidence labels per cell are graded as follows. HIGH means at least two primary-source citations with a named buyer, named seller or target, and a transaction date. MEDIUM means one primary-source citation with the other facts inferred from a trade press summary. LOW means a single trade press citation with no sponsor confirmation. GAP means the original briefing claim could not be verified at all in 2024 to 2026 primary sources and is moved to Section 19.

The cycle volume baseline uses the CDC National ART Surveillance System (NASS) 2022 federal reporting year because that is the most recent complete federal release as of June 16, 2026 (CDC NASS). Where 2023 cycle data is referenced, the source is the Society for Assisted Reproductive Technology (SART) CORS dashboards (SART 2023 outcomes). PE penetration percentages come from the Bhargava et al article published in Fertility and Sterility in December 2025 (Fertility and Sterility 2025).

Deal-flow assembly drew from PitchBook profile pages, PrivSource transaction notices, PR Newswire and BusinessWire releases, and trade press summaries by Fertility Bridge and AmboyStreet. Every named transaction in Section 11 carries at least one inline source URL. Where a transaction was reported only in trade press without an underlying press release or filing, the trade press citation is flagged in-line and the confidence label is set to MEDIUM rather than HIGH.

Sponsor classification follows three rules. First, the entity that holds majority economic and governance control is named as the current sponsor. Second, co-investors with documented material economic stake (greater than 10 percent) are named alongside the lead. Third, physician owners and management rollover equity are noted where the percentage is disclosed. This is meaningfully stricter than industry trade press, which often conflates lead sponsors, co-investors, and lenders.

For the donor-egg, surrogacy, and cryopreservation lines, the tracker covers ancillary lines only where they are part of a tracked PE platform’s vertical (My Egg Bank inside Inception/Prelude, Pinnacle Egg Bank inside Pinnacle, Ovation inside US Fertility). Standalone ancillary platforms (Donor Egg Bank USA, Fairfax EggBank, NW Cryobank) are referenced as potential targets in Section 13 Finding 1 but are not subject to the same row-by-row verification, because the tracker’s scope is PE platforms rather than the universe of all fertility businesses.

3. Macro Spine: What the Sector Actually Looks Like

Closest sibling tracker: OB-GYN and women’s health are the sister sector to fertility/IVF; Dobbs created bifurcated state-by-state M&A geography. See the 2026 OB-GYN PE Roll-Up Tracker.

The CDC National ART Surveillance System is the only mandatory, federally audited dataset on assisted reproductive technology in the United States. In reporting year 2022, 457 reporting US clinics performed 435,426 assisted reproductive technology cycles on 251,542 unique patients, producing 94,039 live-birth deliveries and 98,289 live-born infants (CDC NASS 2022 release). Those infants represented approximately 2.6 percent of all US births that year. Of the 435,426 cycles, 184,423 were egg or embryo banking cycles in which all resulting eggs or embryos were frozen for future use rather than transferred fresh.

For the 2023 reporting year, SART CORS national summaries are currently the only published source because CDC NASS lag runs roughly 24 to 36 months. SART CORS reports that for patients younger than 35, the national average live-birth rate per intended retrieval was 36.9 percent for autologous fresh transfers in 2023 (SART 2023 outcomes). Contemporary OB/GYN, citing SART, reported that aggregate cycle volume rose roughly 6 percent in 2022 versus 2021 (Contemporary OB/GYN). The 2021 CDC summary covered 453 clinics (CDC 2021 ART summary), so the 2021 to 2022 trend was four net additional reporting clinics and roughly 25,000 additional cycles.

The most consequential academic finding for sponsor diligence is in the Bhargava, Patel, and colleagues study published in Fertility and Sterility in December 2025. Using SART data, the authors reported that by the end of 2023, 163 of the roughly 508 SART-member clinics, or 32.1 percent, were private-equity affiliated, and those clinics performed 54.0 percent of all IVF cycles nationally, up from 13.3 percent in 2013 (Bhargava et al, MedicalXpress summary). In 14 states plus DC, half or more of all fertility clinics are PE-affiliated, with cycle share running 63 to 100 percent in those geographies. Rewire News covered the data release in February 2026 as a milestone moment for the field (Rewire News).

Demographics on the demand side are stable but constrained. The CDC’s natality data shows total US births at approximately 3.6 million per year through 2022 to 2024, with the total fertility rate hovering at 1.62 children per woman in 2023, below the population replacement rate of 2.1. Age at first birth is rising and the share of births to women 35 and older has climbed steadily for two decades. Each of those demographic tailwinds increases the demand pool for fertility care: women starting families later have a higher probability of needing assisted reproductive technology, donor cycles, or fertility preservation. The CDC NASS dataset shows ART cycles rising from 326,468 in 2019 to 435,426 in 2022, a 33 percent increase over three years (CDC NASS). That growth rate is well above any other US healthcare service line of comparable size.

Patient acquisition cost is the offsetting force on volume growth. Multi-cycle IVF treatment plans range $20,000 to $40,000 cash-pay before medications, and average self-pay patients spend $60,000 to $100,000 on multi-cycle treatment over 18 to 24 months. The Mercer 2024 survey reports that 47 percent of large employers covered IVF in 2024, leaving 53 percent of large-employer covered lives still on cash-pay economics or partial employer support (Mercer 2024). The mid-market and small-employer pool remains largely cash-pay. The cycle-volume growth pattern from 2019 to 2022 (33 percent over three years) is therefore best explained by employer benefit expansion plus state mandate expansion, not by underlying demographic shift. That distinction matters for 2026 underwriting because employer benefit expansion has slowed (45 to 47 percent year-on-year per Mercer), so the next leg of cycle volume growth depends on state mandates such as California SB 729 rather than continued employer expansion.

The implication for any new platform LBO at this stage is direct: the platform-formation phase of PE penetration is essentially complete, and the sector is now in a phase that PitchBook framed in Q2 2024 as “ancillary services” rather than new clinic platforms (PitchBook ancillary services thesis). Section 13 returns to this point with the contrarian view on cryopreservation banks, donor agencies, and embryology lab networks.

4. The Alabama IVF Watershed: LePage and SB159

On February 16, 2024, the Alabama Supreme Court issued its opinion in LePage v. Center for Reproductive Medicine, P.C., holding that “extrauterine embryos” qualify as children under Alabama’s Wrongful Death of a Minor Act (Justia LePage). The factual record involved a 2020 incident at a Mobile-area fertility clinic in which an individual gained access through an unsecured door and dropped frozen embryos on the floor (Goodwin Law alert). The opinion was the first state supreme court ruling treating IVF embryos as persons after the Dobbs decision restored states’ authority over reproductive policy.

ASRM and ACOG both opposed the ruling within days of issuance (ASRM statement). Three Alabama IVF clinics suspended embryo transfer or storage operations during the exposure window. On March 7, 2024, the Alabama Legislature passed SB159, which granted civil and criminal immunity to individuals and entities for embryo damage in connection with IVF treatment (Health Law Advisor). The window from ruling to legislative fix was three weeks.

Sixteen states introduced more than 40 bills in 2024 with fetal-personhood language spanning child-support, tax-credit, wrongful-death, fetal-homicide, and TANF eligibility categories (Cornell JLPP analysis). In response, Tennessee, Georgia, Louisiana, and Nevada passed laws affirming IVF access; Colorado, Tennessee, and Georgia affirmed fertility-care rights; Louisiana modernized its IVF statutes with provider protections (MultiState Insider 2025 review, Fertility Bridge legislation trends).

The protective-state map post-LePage now includes Alabama (via SB159), Tennessee, Georgia, Louisiana, Nevada, and Colorado as states with explicit IVF protection statutes. Texas and Florida remain the largest IVF markets without an analogous protective statute as of June 2026. Texas accounts for an estimated 6 to 8 percent of US ART cycles per the CDC NASS 2022 dataset (CDC NASS); Florida runs slightly behind Texas. The combined Texas plus Florida exposure for IVI RMA (RMA Texas plus RMA Florida) plus US Fertility’s Texas presence plus Pinnacle’s Florida HQ and Texas footprint represents the largest single concentration of LePage-style state-supreme-court tail risk in the sector.

One under-discussed implication is the timing question for any platform contemplating exit in 2026. A Texas LePage-equivalent ruling would compress comparable transaction multiples across the sector for the duration of any legislative-fix window. Sellers exiting before a Texas ruling capture the current multiple environment; sellers waiting and absorbing a ruling pay the discount. Buyers face the inverse calculus. This is the same logic that has driven exit timing in adjacent regulated sectors after similar judicial events.

The Goodwin Law analysis of LePage also notes that the decision creates discovery exposure: if frozen embryos are children for wrongful death purposes, then clinics may face heightened standard of care obligations on storage, handling, and disposition. The downstream effect is increased E&O premiums and an effective rise in clinic-level operating cost (Goodwin Law alert). Diligence on Alabama-domiciled or Texas-domiciled platforms should request line-item insurance cost trends through 2024 and 2025 to quantify the implicit risk pricing.

The implication for sponsor underwriting is that LePage applied only to Alabama, but a similar opinion from Texas or Florida supreme courts would directly affect the IVI RMA Texas footprint, US Fertility’s Texas practices, Pinnacle’s Texas network, and any independent Texas clinic. Most LBO models do not stress test a 12-month suspension scenario in a single mandate-absent state, and that omission is now a diligence gap rather than a tail risk. Section 13 Finding 2 returns to this point.

5. California SB 729: The Dominant 2026 Catalyst

California Senate Bill 729 was signed in 2024 and was originally scheduled to take effect July 1, 2025. After two delays it now takes effect January 1, 2026 for fully-insured large-group plans, and July 1, 2026 for state-employee plans (Sequoia SB 729 update). SB 729 extends IVF coverage to fully-insured large-group plans, which under California’s split insurance market covers a meaningful portion of California’s roughly 90,000 annual ART cycles. California alone accounts for an estimated 18 to 20 percent of US ART cycle volume per the CDC NASS 2022 dataset (CDC NASS).

The SB 729 effective date converts a large slice of California demand from cash-pay to mandate-paid economics. Platforms with concentrated California exposure include HRC Fertility, Spring Fertility, IVI RMA California (the former Reproductive Medicine Associates of Northern and Southern California), and Pinnacle’s California Fertility Partners. Each of those platforms underwrites a meaningful share of revenue at cash-pay California rates today.

The first-order effect is volume growth as previously price-sensitive patients use coverage. The second-order effect is blended price compression as more cycles run through payor fee schedules rather than self-pay. The third-order effect that most diligence models miss is variable cost: the marginal mandate cycle is profitable only if the contracted reimbursement rate sits above practice-level variable cost, and California cost structure for embryology lab time, anesthesia, and REI labor is among the highest in the country. The reason SB 729 has now been delayed twice (originally July 1, 2025; then January 1, 2026; then July 1, 2026 for state-employee plans) is precisely that the payor side has needed time to model the cost. That implementation risk remains material as of mid-2026 and is not yet in any platform’s underwriting model.

A fourth-order effect deserves attention: SB 729 will likely drive consolidation pressure within California even faster than the national rate. Independent California clinics that have operated profitably on cash-pay economics will now face simultaneous contract negotiations with multiple commercial payors, in-network credentialing requirements, and prior-authorization workflows that they may not be staffed to handle. Smaller California clinics are therefore plausible add-on targets for IVI RMA California, Pinnacle, and HRC over the 2026 to 2027 window as the operational complexity of mandate implementation pushes founder-physicians toward platform partnerships.

The legislative history of SB 729 is also instructive. The bill was introduced in 2023 and signed in 2024, with the original July 1, 2025 effective date moved to January 1, 2026 in mid-2025, then further moved to July 1, 2026 for state-employee plans in late 2025 (Sequoia SB 729 update). Each delay has been justified by implementation feasibility concerns rather than policy reversal. The cumulative pattern suggests California regulators are willing to delay enforcement but not to abandon the mandate, which is itself a useful signal for diligence: SB 729 risk is timing risk, not policy reversal risk, at least under current state leadership.

Sister-mandate states to watch for 2026 to 2028 policy expansion include Washington (active proposals as of 2025), Oregon (early-stage bills), and Pennsylvania (active committee work). Each of those would extend the IVI RMA footprint or the regional cash-pay-to-mandate transition. The pattern is that mandate expansion tends to follow Democratic legislative majorities and to lag behind Massachusetts and Maryland by 8 to 12 years per state.

6. Federal Right to IVF, FEHB Expansion, State Mandates, and the RESOLVE Map

The Right to IVF Act was introduced in June 2024 by Senators Tammy Duckworth, Patty Murray, and Cory Booker. The bill bundled three measures: the Access to Family Building Act, the Access to Infertility Treatment and Care Act, and the Family Building FEHB Fairness Act (Duckworth press release). Senate Republicans blocked the package in June 2024 and again in September 2024. The Biden-Harris administration responded by expanding IVF coverage to FEHB-eligible federal employees in September 2024 (Duckworth FEHB expansion).

President Trump signed an executive order on February 18, 2025 directing the White House Domestic Policy Council to develop, within 90 days, policy recommendations to lower IVF out-of-pocket cost and reduce plan burden (AJMC). A subsequent October 2025 White House fact sheet announced an agreement with EMD Serono to reduce out-of-pocket IVF medication cost (White House fact sheet). No federal statutory IVF coverage mandate has been enacted as of June 16, 2026. Because federal action has stalled, state-by-state expansion is the only practical lever for the next 18 to 24 months, and California SB 729 is the most consequential state in that set.

State Insurance Mandates and the RESOLVE Map

As of late 2025, 22 states plus the District of Columbia carry IVF coverage mandates on the books, with another three states requiring infertility-diagnosis coverage that excludes IVF (RESOLVE state coverage map). MultiState’s November 2025 review of fertility legislation noted that 2025 brought meaningful expansion: the DC mandate took effect January 1, 2025 for all individual, small-group, and large-group plans; Maryland’s 2024 amendment removed barriers for same-sex couples and donor cycles; Utah’s 2024 amendment expanded infertility treatment and fertility preservation rules (MultiState review).

Mandate states tend to operate closer to payor utility economics, with practices receiving negotiated fee schedules from commercial payors and Blue Cross plans. Non-mandate states retain more cash-pay pricing power. The result is that platform economics are not uniform across the network: a Pinnacle clinic in Tampa Florida runs different unit economics than a Pinnacle clinic in California after SB 729 enforcement. Diligence models that apply a single blended EBITDA margin across the entire network understate cyclical sensitivity to mandate enforcement timing.

The Mercer Survey on Health and Benefit Strategies for 2025, released in November 2024, reports that 47 percent of all large employers and 70 percent of the largest employers (5,000 or more lives) covered IVF in 2024, up from 45 percent and 62 percent respectively in 2023 (Mercer 2025 survey). Pre-conception planning will be offered by 35 percent of large employers in 2025, men’s fertility testing coverage by 35 percent, sperm freezing by 20 percent, and egg freezing by 19 percent. Mercer’s 2025 maintenance survey suggests stable benefits in 2025 (Mercer maintenance survey). The slowdown from a 45-to-47 percent year-on-year move, against the 2019-to-2023 doubling, indicates an employer coverage plateau rather than continued S-curve growth.

7. PE Share: 32.1 Percent of Clinics, 54 Percent of Cycles

The Bhargava et al article in Fertility and Sterility December 2025 is the only peer-reviewed measurement of PE clinic share and cycle share to date (Bhargava et al full text). The authors used SART CORS data through 2023 and matched ownership against PitchBook and trade press. By end of 2023, 163 of approximately 508 SART-member clinics, or 32.1 percent, were PE-affiliated, and those clinics performed 54.0 percent of all IVF cycles nationally. The clinic share was 13.3 percent in 2013, meaning PE clinic share more than doubled in 10 years and cycle share more than quadrupled.

The cycle-share-to-clinic-share ratio (54.0 divided by 32.1, or roughly 1.68) tells the operating story: PE clinics run heavier cycle volume per site than non-PE clinics. That is consistent with a thesis under which PE platforms run more cycles per REI through standardized protocols, dedicated embryology labs, and centralized patient acquisition. The PMC literature review on PE in fertility from August 2025 documents the same dynamic and adds that PE-affiliated networks operate larger embryology lab footprints with higher cycle throughput (PMC PE in fertility literature review). Fertility Bridge’s 2024 ownership list is the practitioner-facing version of the same dataset (Fertility Bridge 2024 ownership list).

The implication for new platform formation is that the addressable universe of independent multi-clinic groups large enough to anchor a platform LBO is now small. The remaining independent universe is heavily concentrated in single-clinic or two-clinic operators, which favors a tuck-in strategy at 7x to 9x EBITDA over new platform formation at 10x to 12x EBITDA. Section 12 returns to multiples.

A second implication is geographic. Bhargava et al’s finding that 14 states plus DC carry half or more of their clinics under PE ownership with 63 to 100 percent cycle share is concentrated in larger metro markets. The remaining single-clinic and two-clinic targets are mainly in secondary metros and college towns. Tuck-in pricing in those markets is correspondingly lower because of weaker cash-pay density and longer ramp to cycle volume. PE buyer behavior in 2024 and 2025 reflects this: the IVI RMA Southern California add-ons (Reproductive Health and Wellness Center, Rise Fertility, Halo Fertility) and the HRC Fertility-Silicon Valley acquisition both targeted established Bay Area and Los Angeles practices rather than greenfield secondary metros (PrivSource, Fertility Bridge pipeline).

The third implication is sponsor competition at the platform level. When the universe of independent multi-clinic groups shrinks, sponsor-to-sponsor transitions become the dominant deal type. The Eugin/Boston IVF sale from Fresenius Helios to KKR/IVI RMA plus GED Capital in January 2024 (BusinessWire) and the L Catterton co-investment alongside Amulet at USF in December 2025 (Fertility Bridge) are both sponsor-to-sponsor transitions rather than founder-to-sponsor entries. Section 13 returns to the question of whether the next sponsor-to-sponsor cycle is sponsor-to-strategic instead.

8. Active 2024 to 2026 PE Platforms (Big Table)

The platforms below are ordered by US cycle volume and clinic count. Each row has been verified against a sponsor portfolio page, a transaction document, or a named press release. Rows where the original briefing claim could not be verified are flagged in Section 19.

9. Platform Profiles: US Fertility, IVI RMA, Inception, Pinnacle, CCRM

US Fertility (USF) | Amulet Capital + L Catterton

USF is the largest pure-play US fertility platform by clinic count and cycle volume. The platform was formed in May 2020 when Amulet Capital Partners partnered with Shady Grove Fertility, the dominant Mid-Atlantic clinic group founded by REIs Michael Levy and Robert Stillman (BusinessWire formation). In April 2023, USF agreed to combine with Ovation Fertility, a lab-services platform that Morgan Stanley Capital Partners had backed since 2019 (Morgan Stanley Ovation press release, PR Newswire USF Ovation). The Ovation combination gave USF a vertically integrated embryology lab footprint, an important workforce play given embryologist scarcity (Section 14).

In November 2025, USF announced a strategic partnership with L Catterton as co-lead alongside Amulet, with USF physician partners retaining substantial ownership (Amulet press release, PR Newswire). The transaction closed on December 30, 2025 (Fertility Bridge close detail). Fertility Bridge reports L Catterton acquired 42.5 percent and physicians and management retain 15 percent. The financing structure was an $825 million first-lien term loan B due 2032 plus $1.71 billion of new cash and rollover equity. USF is expected to do close to $1 billion of 2026 revenue and operates 121 IVF clinics and labs across 20 states with more than 200 physicians (PR Newswire). Moelis advised USF and Amulet (Moelis transaction page); Harris Williams advised L Catterton (Harris Williams transaction page).

Sponsor attribution correction: USF is not, and has never been, a Lee Equity portfolio. The Lee Equity reference in some prior summaries appears to confuse Lee Equity’s separate Prelude/Inception investment (Section 10 below). The Patricia Industries reference that appears in some older briefings for the CCRM line cannot be verified for USF either. The actual USF cap table is Amulet Capital Partners plus L Catterton plus physician owners as of December 30, 2025.

IVI RMA Global (US: RMA + Boston IVF) | KKR (majority) + GED Capital

KKR acquired IVI-RMA Global from Investindustrial in a 2022 transaction valued at roughly $3 billion (Jones Day deal page). On January 31, 2024, IVI RMA closed its acquisition of the North American operations of Eugin Group, including Boston IVF and Toronto-based TRIO, for approximately $535 million, with GED Capital co-investing alongside KKR/IVI RMA in the Eugin transaction (BusinessWire IVI RMA Eugin, Healthcare Business International, AmboyStreet top-10 2024 deals).

The US-segment, RMA, operates 25 fertility centers across New Jersey, Pennsylvania, Florida, Texas, California, and Washington per the PMC literature review (PMC review). Boston IVF adds the New England footprint. In January 2025, IVI RMA North America announced acquisitions of Reproductive Health and Wellness Center, Rise Fertility, and Halo Fertility from Global Premier Fertility, extending the Southern California presence (PrivSource transaction). IVI RMA Global also acquired ART Fertility Clinics for $400 to $450 million in 2025 (Fertility Bridge 2025 pipeline); ART Fertility Clinics is Middle East and India focused but rolls up into the same KKR-backed parent.

The September 2025 departure of three Boston IVF REIs to launch Terra Fertility as an independent practice is the first documented physician spin-out from a KKR-owned clinic post-Eugin close and is the leading indicator to monitor for the broader REI retention thesis (Fertility Bridge 2026 trends). Section 13 returns to physician retention modeling.

Inception Fertility / Prelude Network | Lee Equity Partners

Lee Equity Partners launched Prelude with founder Martin Varsavsky in October 2016 by acquiring Reproductive Biology Associates of Atlanta and My Egg Bank North America (PR Newswire Prelude launch). Prelude was combined with Inception Fertility (founded by TJ Farnsworth) shortly after, with Inception as the parent holding company. Lee Equity has been backing Inception and Prelude since the merger and was reported by Axios as having sought a buyer in July 2022, though no transaction closed (Axios).

As of mid-2026, Lee Equity remains the majority sponsor and Fertility Bridge cites Inception among networks preparing for exit alongside Kindbody and Pinnacle (Fertility Bridge 2026 trends). The MSD Capital reference that appeared in older briefing material cannot be verified in any 2024 to 2026 primary source; that attribution is moved to Section 19.

Inception’s Prelude Network acquired Sincera Reproductive Medicine in 2023 to anchor greater Philadelphia (PR Newswire Sincera) and Reproductive Science Center of New Jersey in 2024 with Dresner Partners advising (Yahoo Finance Dresner). Six fertility specialists from the REI Fellowship Class of 2024 joined Prelude; the network has 40 physicians named to the 2024 Castle Connolly Top Doctors list and 10 clinics in Newsweek’s 2024 America’s Best Fertility Clinics list (Fertility Bridge). PitchBook lists Inception cumulative funding at roughly $499 million (PitchBook Inception profile).

Pinnacle Fertility | Webster Equity Partners

Webster Equity Partners is the sole institutional investor in Pinnacle Fertility. Webster’s own portfolio page lists Pinnacle (Webster portfolio). Jerry Rhodes, a Webster Operating Executive, sits on the Pinnacle board (Webster bio Rhodes). The Welsh Carson Anderson and Stowe (WCAS) attribution in some prior reports is incorrect. WCAS’s healthcare track record in 2024 to 2025 went into AssistRx in February 2024 and Constitution Surgery Alliance in June 2025 (Tracxn WCAS acquisitions).

Pinnacle was founded in 2021 and is headquartered in Tampa Florida. Its network exceeded 40 clinics by mid-2026 across the country (Pinnacle press). Recorded Pinnacle add-ons through 2024 to 2025 include the Institute for Human Reproduction (Chicago), IVF1 (Naperville, Illinois), Center for Reproductive Care (Chicago), California Fertility Partners (per Bailey and Company at BNCo deal page), Oma Fertility, and IVF Michigan and Ohio Fertility Centers in March 2025 (PrivSource IHR, PrivSource IVF1). PitchBook records Pinnacle’s most recent close as Tulsa Fertility Center on November 14, 2025 (PitchBook Pinnacle). Fertility Bridge places Pinnacle among networks preparing for exit (Fertility Bridge 2026).

Pinnacle’s segmentation is wider than a pure clinic operator: the Pinnacle Egg Bank and Pinnacle Surrogacy units are separately branded ancillary lines that capture donor and gestational-carrier economics inside the same parent. That vertical integration is one reason Pinnacle is widely modeled as an exit candidate at a higher multiple band than a clinic-only operator.

Pinnacle’s California exposure is notable for the SB 729 catalyst discussion in Section 5. California Fertility Partners runs out of West Los Angeles and Beverly Hills under physician leadership that long predates the Pinnacle acquisition. Pinnacle’s other California exposure runs through Oma Fertility on the Central Coast and the Northern California footprint built up through 2023 and 2024. The combined California cycle count inside Pinnacle is not publicly disclosed but is widely modeled in the high single-digit thousands per year, making Pinnacle one of the four most California-exposed PE platforms alongside HRC Fertility, Spring Fertility, and IVI RMA California.

Pinnacle’s Midwest footprint became more meaningful with the March 2025 affiliation of IVF Michigan and Ohio Fertility Centers, which added one of the more established Midwest fertility networks to the Pinnacle group (Fertility Bridge pipeline). The November 14, 2025 Tulsa Fertility Center close extended Pinnacle into Oklahoma, a non-mandate state with cash-pay pricing power but lower cycle density than the Pinnacle California or Illinois footprints (PitchBook Pinnacle).

Kindbody | Perceptive Advisors (debt) + GV + RRE Ventures

Kindbody is the operating outlier in the Section 9 table because it combines an employer fertility benefit manager business with an owned clinic network, a hybrid that no other platform in the sector runs at scale. Kindbody raised a $100 million Series D led by Perceptive Advisors in March 2023 at a $1.8 billion valuation (PR Newswire Kindbody). Cumulative funding totals approximately $315 million per Tracxn (Tracxn Kindbody).

The 2022 Vios Fertility acquisition doubled Kindbody’s clinic footprint and reportedly drove operational strain (Sacra Kindbody). Bloomberg’s “IVF Disrupted: The Kindbody Story” reporting in 2024 documented operational issues including mislabeled, lost, or destroyed embryos. Kindbody undertook an operational reset through 2024 and 2025, including a leadership reshuffle and a tighter focus on the benefits business. Fertility Bridge places Kindbody among networks preparing for exit (Fertility Bridge 2026 trends).

The most interesting Kindbody question for diligence is whether the benefits-side business and the clinic-side business should be sold separately. The benefits-side business carries a vertical SaaS multiple ceiling closer to Progyny and Carrot; the clinic-side business carries a clinic-platform multiple ceiling closer to the 10x to 12x EBITDA band. Selling the parts separately could plausibly maximize sponsor proceeds against either a Progyny acquisition of the benefits side or a USF or Pinnacle acquisition of the clinic side. That bifurcated exit thesis is not in the Kindbody press but is consistent with the 12 to 24 month sponsor-to-strategic path described in Section 13 Finding 4.

Spring Fertility | Wildcat Capital Management + founder majority

Spring Fertility took a significant growth equity investment from Wildcat Capital Management, a New York family office, in August 2023. Founders Klatsky and Tran retained majority ownership post-transaction (Spring Fertility press release). No 2024 to 2025 ownership change is documented in primary sources. Spring is concentrated in the San Francisco Bay Area and New York metro and is a frequent Bay Area pricing benchmark for cash-pay cycles.

The Spring Fertility positioning matters for the SB 729 discussion because Spring runs at the upper end of Bay Area cash-pay pricing. The proportion of Spring’s California cycles that migrate from cash-pay to mandate-paid is the operational question for Spring’s 2026 EBITDA. Spring’s egg-freezing focus partly insulates the platform from the SB 729 cycle-mix question because planned egg freezing is largely cash-pay even in mandate states, with employer benefits (Progyny, Carrot, Maven) covering a meaningful subset of urban-professional patients.

HRC Fertility | Jinxin Fertility (HKEX: 1951)

HRC Fertility joined forces with Jinxin Fertility in 2017 via a Hong Kong Exchange listing (HKEX: 1951). HRC Fertility Management remains headquartered in Pasadena, California. HRC acquired Dr. Cristo Zouves’s single-provider Bay Area practice in March 2025, branded as HRC Fertility-Silicon Valley (Fertility Bridge pipeline). HRC is publicly traded via its Jinxin parent rather than US PE owned. The Jinxin parent carries cross-border regulatory exposure that pure US PE platforms do not face, particularly around capital outflows from mainland China and currency hedging on US-dollar receivables.

CCRM Fertility | Unified Women’s Healthcare (Altas + Ares + Oak HC/FT)

Unified Women’s Healthcare acquired CCRM Fertility on September 10, 2023 for $775 million (World IVF Life Sciences Business). The Unified-CCRM strategic partnership was originally announced in 2021 (BusinessWire 2021 partnership). Unified itself is backed by Altas Partners, the Private Equity Group of Ares Management Corporation, and Oak HC/FT (Unified press).

The Patricia Industries reference that appeared in some older briefing material is unverified in primary sources and is moved to Section 19. CCRM was previously a TA Associates portfolio company (TA Associates page) and that link via TA is the legacy investor identifier. CCRM continues to add at the practice level, including the RADfertility acquisition spanning Delaware and Maryland (CCRM RADfertility press).

10. Segment Breakdowns

The sector decomposes into six functional segments that are increasingly traded as separate cash-flow streams rather than as a single fertility-clinic asset class.

IVF clinic operators. The platform layer is dominated by US Fertility, IVI RMA, Inception/Prelude, Pinnacle, and CCRM/Unified, with HRC and Spring as regional specialists and Kindbody as a hybrid. This is where the Bhargava et al 32.1 percent and 54 percent figures concentrate (Bhargava et al). Multiples currently sit in the 10x to 12x EBITDA platform band per PitchBook Q2 2024 with smaller groups at 7x to 9x EBITDA (PitchBook Q2 2024).

Donor and surrogacy services. My Egg Bank North America (inside Inception/Prelude), Donor Egg Bank USA, Fairfax EggBank, Pinnacle Egg Bank (inside Pinnacle), and Pinnacle Surrogacy are the primary named donor and surrogacy entities. The donor-egg supply side is structurally short, especially for ethnic-match cycles, and donor brokerages carry gross margins north of 60 percent per industry roll-up references in the Fertility Bridge 2025 pipeline note (Fertility Bridge pipeline).

Cryopreservation banks. Egg, sperm, and embryo cryopreservation is increasingly modeled as a recurring-revenue annuity inside larger platforms. The vertically integrated banks (My Egg Bank under Inception, Pinnacle Egg Bank under Pinnacle, Ovation lab under USF) capture this stream inside the parent. Standalone banks are the next-wave roll-up target per Section 13 Finding 1. The CDC NASS 2022 release reported that 184,423 of the 435,426 cycles were egg or embryo banking cycles, or 42.4 percent of all cycles (CDC NASS). That share is rising as patients increasingly choose preservation.

Egg-freezing-focused operators. Spring Fertility, Extend Fertility (under Inception), and Kindbody all market a planned-egg-freezing line as a distinct entry point. The economics are different from the pure-IVF cycle: lower per-cycle revenue, higher patient acquisition cost, longer recurring storage revenue. This segment carries a Bay Area and New York urban-professional concentration that does not translate cleanly to mandate states.

LGBTQ+ specialty platforms. Reciprocal IVF, gestational carrier coordination, and gender-affirming fertility preservation are increasingly broken out as line items inside the IVI RMA, Pinnacle, USF, and Kindbody platforms rather than separate platforms. The benefit side (Carrot, Maven) explicitly markets inclusive language, and the Mercer 2024 survey notes that 64 percent of large employers offering fertility benefits intend them as inclusive, with eligibility not limited to clinical infertility definition (Mercer 2024).

Digital fertility benefits managers. Progyny, Carrot, and Maven sit on the benefits side of the negotiating table from the clinic operators. Progyny is the only publicly traded comparable, with 2025 revenue of $1,288.7 million, up 10 percent versus 2024’s $1,167.2 million, and 2026 guidance of approximately 600 clients and 7.2 million members (Progyny Q4 2025 release). Carrot expanded its network to 4,200 providers in August 2025 (Carrot provider expansion). Maven raised $125 million in 2024 at a $1.7 billion valuation (Maven Wikipedia).

The benefits-side market is structurally bifurcated. Progyny is the incumbent with the largest covered-lives pool and the deepest payor contracting infrastructure. Carrot has built a wider provider network than Progyny on paper (4,200 providers versus Progyny’s clinic relationships) but with less price discipline; Carrot’s economic model relies more heavily on flexible fund design than on negotiated discount aggregation. Maven sits adjacent rather than head-on, marketing a broader women’s and family health benefit suite with fertility as one module among many (maternity, postpartum, pediatrics, menopause). The three platforms compete for overlapping employer contracts but not for identical product positioning.

The market share question is partially answerable from public filings. Progyny’s roughly 7.2 million covered lives at 2026 guidance represents perhaps 4 to 5 percent of the US large-employer covered-lives pool. Carrot and Maven’s combined covered lives are not publicly disclosed but trade press estimates place the combined three-vendor universe somewhere between 12 and 18 percent of large-employer covered lives. That leaves the majority of large-employer fertility benefits still administered in-house by the employer or directly contracted with TPAs, which is precisely the addressable expansion opportunity. The Mercer 47 percent of large employers covering IVF figure (Mercer 2024) is therefore the universe ceiling, not the floor.

11. Deal Flow Timeline 2024 to 2026

The most consequential transaction of the cycle is the L Catterton co-investment in US Fertility alongside Amulet Capital Partners, which closed December 30, 2025 (Fertility Bridge USF L Catterton, Harris Williams). The transaction effectively recapitalized the platform and reset the hold-period clock without a full exit, indicating Amulet was not willing to walk away from sector exposure at this stage of the cycle.

Other named 2024 to 2026 transactions:

• IVI RMA / Eugin Group acquisition closed January 31, 2024 at $535 million with Boston IVF and TRIO included (BusinessWire IVI RMA Eugin, AmboyStreet). Sponsor-to-sponsor transition: Fresenius Helios sold to KKR/IVI RMA plus GED Capital.
• Prelude Network acquires Reproductive Science Center of New Jersey in 2024, advised by Dresner Partners (Yahoo Finance Dresner).
• IVI RMA North America acquires Reproductive Health and Wellness Center, Rise Fertility, and Halo Fertility from Global Premier Fertility on January 6, 2025 (PrivSource). Three Southern California clinics; terms undisclosed.
• HRC Fertility acquires Dr. Cristo Zouves’s single-provider practice (now HRC Fertility-Silicon Valley) in March 2025 (Fertility Bridge).
• Pinnacle Fertility acquires IVF Michigan and Ohio Fertility Centers (strategic affiliation) in March 2025, and Tulsa Fertility Center via Buyout/LBO on November 14, 2025 (PitchBook Pinnacle).
• IVI RMA Global acquires ART Fertility Clinics in 2025 at $400 to $450 million (Middle East and India footprint into the KKR parent) (Fertility Bridge pipeline).
• Three Boston IVF REIs depart to launch Terra Fertility (independent practice) in September 2025 (Fertility Bridge trends). This is the first documented physician spin-out from a KKR-owned clinic post-Eugin close and a leading indicator worth monitoring.
• Progyny tuck-ins: $5.3 million on business acquisitions in Q3 2024 and $9.3 million in Q2 2025; target names not disclosed in 10-Q filings (Progyny 10-K).
• INVO Bioscience and NAYA Biosciences merger reversal in April 2025 (six months post-announcement) (Fertility Bridge pipeline). Notable as a busted deal in an otherwise active 2024-2026 window.
• US Fertility / L Catterton co-lead closes December 30, 2025 (Fertility Bridge). $825M TLB plus $1.71B cash and rollover equity.

Dresner Partners flagged four to five additional fertility transactions in negotiation as of mid-2025, with some at letter-of-intent stage; MidCap Advisors indicated two to three smaller practice deals under development (Fertility Bridge pipeline). Eleven North American fertility deals were agreed in the first nine months of 2024 versus 13 in the same period of 2022 (PitchBook). 2025 deal count came in lower as PE platforms shifted from platform creation to ancillary services bolt-ons.

The 2024 to 2026 deal calendar also includes two transactions worth flagging that have not closed as of mid-2026. The Inception Fertility exit process referenced in the Axios July 2022 report (Axios) appears to have re-opened in 2025 per Fertility Bridge’s “preparing for exit” language (Fertility Bridge). No buyer has been named. The Pinnacle exit, also referenced by Fertility Bridge as in the exit window, has been the subject of intermittent banker chatter for 12 months without a named buyer. Kindbody’s exit window is the third open process. All three exits are at the platform level rather than the add-on level, and the universe of credible buyers at that scale is small: KKR could re-up at IVI RMA; Amulet and L Catterton just recapitalized USF and are unlikely buyers; CCRM is inside Unified and Unified is itself inside Altas/Ares/Oak HC/FT; that leaves Webster, Lee Equity, Wildcat, or a strategic payor (Optum, Aetna, Evernorth) as the realistic counterparty universe.

The sponsor-to-strategic exit thesis described in Section 13 Finding 4 is therefore not speculative. The actual realized universe of platform-level financial buyers is small enough that any one of the three open exits (Inception, Pinnacle, Kindbody) clearing through a payor would re-rate the multiples on the remaining two. Conversely, all three clearing through financial sponsors would compress multiples on the next platform exit (USF or IVI RMA) by tightening the auction.

One additional 2025 datapoint worth flagging: PitchBook records 2024 fertility transaction count at the lower end of the 2020 to 2024 range, and 2025 below that. That is partly a function of the platform-formation phase ending. It is also partly a function of debt-market sticker shock in early 2024 around term loan B pricing for healthcare LBOs, which loosened by Q3 2025 and arguably enabled the L Catterton USF transaction at $825 million TLB pricing. Deal volume in 2026 may rebound on the back of that loosening, with Inception, Pinnacle, and Kindbody all positioned to clear.

The USF financing structure deserves additional commentary because it is the largest single transaction in the cycle and sets the comp for any subsequent platform exit. The $825 million first-lien term loan B due 2032 priced inside healthcare LBO benchmarks for Q4 2025, which trade press placed in the SOFR plus 425 to 475 basis points range for similar tier-2 healthcare service platforms. The $1.71 billion of new cash and rollover equity reflects a recapitalization rather than a clean sale: Amulet retained its stake, L Catterton acquired 42.5 percent per Fertility Bridge, and physician owners plus management retained 15 percent (Fertility Bridge USF L Catterton). That structure preserves alignment with the physician owner base while resetting the hold-period clock for both Amulet and L Catterton.

A second transaction worth noting is the 2025 ART Fertility Clinics acquisition into IVI RMA Global at $400 to $450 million per Fertility Bridge (Fertility Bridge pipeline). While the ART Fertility footprint is Middle East and India focused rather than US, the transaction expands the IVI RMA Global parent’s revenue base and changes the multiple math for any KKR exit of IVI RMA Global. KKR’s original 2022 entry at roughly $3 billion priced the European plus US operations; adding US operations (Eugin/Boston IVF $535 million) plus Middle East/India operations (ART Fertility $400 to $450 million) over 2024 to 2025 has scaled the platform considerably. Any 2027 to 2028 KKR exit of IVI RMA Global at the platform multiple would clear at meaningfully higher absolute value than the 2022 entry.

12. Valuation Multiples

Per the PitchBook Q2 2024 Healthcare Services Report, fertility sector benchmarks are as follows (PitchBook Q2 2024):

• Add-on and minority investments: 7x to 9x adjusted EBITDA.
• Platform transactions: 10x to 12x adjusted EBITDA.
• Smaller clinic groups ($2 to $5 million EBITDA): 7x to 9x EBITDA.
• Larger fertility groups ($10 million plus EBITDA): double-digit multiples.

Specific named reference points for the platform multiple ceiling include Unified Women’s Healthcare paying $775 million for CCRM Fertility in September 2023 (World IVF Life Sciences), KKR paying roughly $3.2 billion for IVI-RMA Global in 2022 (Jones Day), and the Eugin/Boston IVF North American business clearing at $535 million in January 2024 (AmboyStreet).

Cash-pay markets command higher multiples than mandate states because cash-pay practices have demonstrated price elasticity and pricing power, while mandate states such as Massachusetts and Connecticut run closer to payor fee-schedule utility pricing. This is why the Bay Area (Spring Fertility), Texas (RMA Texas), and Florida (Pinnacle) economics underwrite differently from Massachusetts (Boston IVF) or Maryland (Shady Grove). The California SB 729 bull case is precisely that cash-pay California migrates to mandate California, increasing volume but pressuring blended pricing, with the net EBITDA per cycle dependent on whether the marginal mandate cycle clears above practice-level variable cost.

The 2023 published study by Bhargava et al cited 32.1 percent PE clinic share producing 54.0 percent of cycles (Bhargava et al); larger volume per PE-affiliated clinic is itself a multiple driver because it indicates operating efficiency at scale.

On the public-comp side, Progyny carries a fertility benefit manager multiple closer to vertical SaaS than to a clinic operator; that distinction is central to the contrarian view in Section 13. Mertz Taggart, while best known for home-based-care and behavioral-health M&A reporting, has not published a fertility-specific quarterly comparable to its home-health series; that gap leaves PitchBook and Fertility Bridge as the only consistent quarterly trackers (Section 20).

Egg and sperm cryopreservation banks are valued separately from clinic platforms. My Egg Bank North America (in Inception/Prelude) and Pinnacle Egg Bank are vertically integrated rather than standalone. The freestanding US donor egg banks (Donor Egg Bank USA, Fairfax EggBank, NW Cryobank) have been treated as ancillary roll-up targets at lower multiples in the 7x to 9x EBITDA band per PitchBook but with embedded gross margin north of 60 percent. PitchBook’s Q2 2024 thesis pivot from “fertility platform” to “ancillary services” reflects this band (PitchBook).

13. Six Contrarian Findings

Finding 1: PE saturation in fertility happened years ago; the next-wave thesis is ancillary services

PitchBook’s Q2 2024 thesis explicitly states “many prime fertility assets have already been acquired” and that the next opportunity is ancillary services: egg and embryo storage, donor banks, genetic testing, software, embryology-as-a-service (PitchBook ancillary thesis). Combined with the Bhargava et al finding that 32.1 percent of clinics already do 54.0 percent of cycles (Bhargava et al), the clinic-platform phase is essentially over. A new clinic-platform LBO at this stage is buying mature-cycle terminal multiples, not an emerging-platform multiple. The roll-up opportunity sits in cryopreservation banks, donor agencies, and embryology lab networks where PE penetration is still in early innings, with PitchBook’s 7x to 9x EBITDA band for ancillary services and gross margins above 60 percent at standalone donor egg banks.

The specific ancillary segments to watch are: long-term cryopreservation storage (recurring revenue, low capital expense, high gross margin), donor egg agencies (acute supply shortage in ethnic-match cycles), PGT-A and PGT-M genetic testing labs (CooperSurgical and Igenomix-style consolidation), embryology-as-a-service (lab outsourcing to mid-sized clinics), and fertility-specific software (EHR, patient-portal, success-rate analytics). Each of these is a separate roll-up thesis with separate target universes. None of them is currently subject to the supply-side scarcity (REIs, HCLD embryologists) that constrains the clinic-platform thesis.

An adjacent thesis worth flagging is the patient-financing and lending market. Cash-pay IVF treatment plans of $20,000 to $40,000 per cycle generate a recurring patient-financing need that sits outside the clinic platform but is closely correlated with cycle volume. Capital Now, Future Family, and Affirm-style fertility-specific lenders represent another roll-up adjacency where PE penetration is still in early innings.

Finding 2: The Alabama LePage ruling was a watershed, and PE diligence underweights state-level reversal risk

The three-week gap between LePage on February 16, 2024 and Alabama SB159 on March 7, 2024 was long enough to suspend operations at three Alabama IVF clinics (Justia LePage, Health Law Advisor SB159). Sixteen states introduced more than 40 personhood bills in 2024 (Cornell JLPP). The fact that Tennessee, Georgia, Louisiana, Nevada, and Colorado have enacted protective statutes is the bull case; the fact that Texas and Florida have not is the bear case. A Texas LePage equivalent would directly impair RMA Texas (under IVI RMA), US Fertility’s Texas practices, Pinnacle’s Texas network, and any independent Texas clinic. Most LBO models do not stress-test a 12-month suspension scenario in any single mandate-absent state.

The bear case scenario worth modeling is a Texas Supreme Court ruling analogous to LePage, followed by a 12-month legislative-fix window. During that window, multi-state platforms would face: clinic-level operational suspension in Texas; embryo storage and shipment ambiguity for inter-state patients; insurance carrier withdrawal pressure on E&O lines; and patient migration to neighboring states (Louisiana, New Mexico, Oklahoma) with all of the associated travel and timing costs. The plausible EBITDA impact at a Texas-heavy platform is in the range of 8 to 15 percent annual hit during the window. None of the published platform-level marketing materials disclose this exposure as a discrete diligence item.

Finding 3: Progyny is the under-tracked structural disruptor of the clinic-platform thesis

Progyny earned $1,288.7 million of 2025 revenue and guides to 7.2 million covered members in 2026 (Progyny Q4 2025), serving as the negotiated reimbursement gatekeeper for the largest IVF-covering employers. Every clinic platform sits inside Progyny’s network on Progyny’s contractually-negotiated rates. The Carrot expansion to 4,200 providers (Carrot) and Maven at a $1.7 billion valuation amplify the trend. Three benefits-side aggregators now control the access pipeline for employer-funded IVF, which represents 47 percent of large-employer covered lives per Mercer (Mercer 2024). Clinic-platform LBO theses that assume continued pricing power against a consolidated benefits-side counterparty are mispriced.

The pricing-power asymmetry deserves quantification. Progyny’s smart cycle bundles negotiate clinic rates well below cash-pay benchmarks; the spread Progyny captures is the operating margin of its benefits-management business. A clinic platform that fights Progyny’s rates risks losing access to Progyny-covered patients entirely. Once the patient is funneled through Progyny’s network, the clinic platform has no direct relationship with the employer purchaser. This is the same dynamic that PBMs created in retail pharmacy, with predictable margin compression at the clinic-operator layer over time.

The Carrot and Maven competitive positioning extends the asymmetry. Carrot’s flexible-fund model allows the patient to direct spend at any provider, which marginally weakens any single clinic’s negotiating position with Carrot. Maven’s bundled-product positioning means the fertility benefit sits inside a broader benefit suite where the employer’s primary purchasing decision is the suite, not the clinic network. In both cases, the clinic platform is a network participant rather than a contracting counterparty. Over time, this compresses clinic platform pricing power further.

Finding 4: Optum-style strategic acquisition of a fertility platform is the next-wave thesis hiding in plain sight

UnitedHealth (via Optum), CVS (via Aetna), and Cigna (via Evernorth) have all built integrated specialty pharmacy plus clinical-network playbooks in oncology, dialysis, and behavioral health. None has executed the fertility version. With Progyny renewing fewer of the largest clients (the unnamed 2025 non-renewal cost Progyny roughly 14 points of growth) (Progyny Q4 2025), there is a plausible case that the unnamed non-renewer was a payor building out an in-house fertility benefit, with the next logical step being a US Fertility or Pinnacle clinic platform acquisition. The Optum-Inception or Aetna-Pinnacle rumor cannot be verified in primary sources today but should be modeled as a 12 to 24 month sponsor-to-strategic exit path that prices to a strategic premium over the PitchBook 10x to 12x platform band.

The structural reason a payor-to-clinic acquisition is compelling is the cost-control loop. A payor that owns a clinic platform can do three things that an external payor cannot: control case mix through care-pathway redirection, capture lab and pharmacy economics inside the same parent, and align REI compensation with cycle-success metrics that match payor utilization management. The Optum-DaVita oncology model in 2024 to 2025 is the template, with Optum negotiating directly with bundled-payment payors and capturing the spread. A fertility version of the same model would compress the gap between the cash-pay and mandate-paid pricing tiers by giving the payor an in-house low-cost option.

The risk to a strategic transaction is antitrust review. The FTC and DOJ have signaled increased scrutiny of vertical healthcare consolidation, and a payor-clinic platform combination in a sector with a peer-reviewed 32.1 percent PE share would draw HSR review. The 2024 to 2025 increase in HSR notification thresholds has not eased that scrutiny. Diligence on the strategic-exit thesis should price in 6 to 12 months of regulatory review and a meaningful probability of divestiture conditions in concentrated metros.

Finding 5: The REI starting-salary curve from $400K in 2020 to $650K in 2026 is repricing every platform’s underwriting model, and the Terra Fertility spin-out is the leading indicator

Fertility Bridge’s reported figure is approximately a 60 percent increase over five years (Fertility Bridge trends), against a 50 percent fellowship-class capture rate by PE networks (Fertility Bridge fellowship tracking). If clinic productivity per physician does not rise commensurately, EBITDA per physician compresses regardless of cycle volume growth. The Terra Fertility spin-out of three Boston IVF REIs in September 2025 is the leading indicator of the alternative path: founder-physicians can recapture economics by leaving PE-owned platforms once their non-competes expire. Most LBO models assume zero physician attrition. Diligence should model a 5 to 10 percent annual REI departure rate at platforms in the post-2026 cohort.

Finding 6: California SB 729’s January 1, 2026 enforcement date is the single largest 2026 catalyst, and multi-platform California exposure is asymmetric

California performs roughly 18 to 20 percent of US ART cycles. SB 729 converts the majority of fully-insured large-group California demand from cash-pay to mandate-paid (Sequoia SB 729 update). Platforms with heavy California exposure (HRC Fertility, Spring Fertility, IVI RMA California, Pinnacle’s California Fertility Partners) will see volume increase but blended price decrease. The net effect on EBITDA per cycle depends on whether the marginal mandate cycle is at a price above or below practice-level variable cost. The fact that California SB 729 enforcement has now been delayed twice (originally July 1, 2025, then January 1, 2026, then July 1, 2026 for state employees) suggests California implementation risk remains material; that risk is not in any platform’s underwriting model today.

The asymmetry in California exposure is not just about cycle count. Spring Fertility’s Bay Area cash-pay price points are at the top of the national distribution, so the SB 729 transition compresses Spring’s blended pricing more than it compresses Pinnacle’s California Fertility Partners pricing, which already sits closer to mid-tier Los Angeles pricing. IVI RMA California operates a mix of cash-pay and Medi-Cal-adjacent volume that should see less price compression but more volume gain. HRC Fertility, with its Pasadena and new Silicon Valley footprint, sits in the middle. The net winner among these four California-exposed platforms is plausibly HRC, with the Jinxin parent already publicly listed and therefore not facing PE-style exit timing pressure. Spring is the most exposed to price compression and the most reliant on cash-pay scale economics. Pinnacle and IVI RMA California sit between those two extremes.

One specific underwriting question for any 2026 platform exit is whether the diligence package presents Q2 2026 (post-July 1 state-employee plan effective date) actuals or only Q1 2026 (pre-state-employee plan effective date) actuals. The first full quarter under both SB 729 effective dates is Q3 2026, which means any platform exit closing before September 2026 will not have a full-cycle look at mandate enforcement. Sellers may push for pre-effective-date close timing; buyers should resist.

14. Workforce: 1,300 REIs, Embryologist Scarcity, CLIA Director Rule

The REI workforce is the single tightest input on the supply side. ASRM’s 2025 subspecialist scope document cites roughly 1,300 board-certified REIs nationally, with about 60 new fellows entering the workforce each year (ASRM 2025 scope document). The 2024 REI fellowship class graduated 60 fellows from 53 programs; 30 went directly to fertility-center networks, 14 to academic or health-system practices, and 6 to independent clinics, meaning PE-affiliated networks captured 50 percent of the entire 2024 graduating class (Fertility Bridge fellowship tracking). Match competitiveness has tightened: successful match rate has dropped toward 60 percent as applications grew faster than slots (Fertility and Sterility fellowship funding).

The Fertility and Sterility 2025 funding-model paper argues that fellowship program count has failed to expand at the rate of other ObGyn subspecialties, making the REI pipeline structurally constrained (Fertility and Sterility funding model). The Fertility and Sterility “REI in the Year 2035” article quantifies a projected gap between demand and supply (Fertility and Sterility 2035).

BLS does not break out reproductive endocrinology from the broader “physicians and surgeons, all other” line in OEWS. BLS’s May 2024 OEWS reports physicians and surgeons broadly with a median wage at or above the $239,200 ceiling (BLS Physicians OOH). For specialty-level wage, the most cited primary source is the 2021 MGMA Compensation and Production Report, which placed REI median total cash compensation at $461,997. Fertility Bridge reported in March 2026 that incoming REI starting salaries in lower-supply markets have reached $650,000 base plus bonuses, up from a $400,000 average reported in a January 2020 SREI member survey (Fertility Bridge trends). That is roughly a 60 percent increase in starting comp over five years, with implications for platform underwriting on physician retention.

Embryologist supply is the second binding constraint. ABB (American Board of Bioanalysis) is the only CLIA-recognized certifying board for embryology; the relevant certifications are TS (Technical Supervisor), ELD (Embryology Laboratory Director), and HCLD (High-Complexity Laboratory Director). CLIA updates to high-complexity director regulations took effect December 28, 2024, raising the credential bar (ABB). There is no published BLS occupational classification for embryologists; the industry relies on College of Reproductive Biology certification through ABB plus on-the-job training pipelines run by larger lab networks such as Ovation (now within USF), which is itself a vertically integrated talent argument for the USF roll-up thesis.

The embryologist scarcity dynamic interacts with the REI scarcity dynamic in a specific way. An REI can do retrievals and transfers at a higher cycle volume per year if the embryology lab is well-staffed; if the lab is short an HCLD or short ELDs, the REI’s effective cycle capacity falls. Platforms that built or acquired centralized embryology labs (Ovation under USF, the CCRM lab system, the IVI RMA lab network) can spread embryologist capacity across multiple clinics. Platforms that run distributed clinic-by-clinic labs (some Pinnacle clinics, Spring’s individual sites) face higher unit cost on lab staffing and more fragility to individual embryologist resignations.

The December 28, 2024 CLIA high-complexity director rule update is the regulatory accelerant on embryology pricing power. By tightening the credential bar for HCLD designation, CLIA effectively reduced the addressable supply of qualified embryology lab directors. Trade press accounts of HCLD packages in 2025 and into 2026 cite cash compensation in the $400,000 to $600,000 range at the larger platform networks, with sign-on bonuses in the $50,000 to $100,000 band. The premium for a multi-clinic HCLD who can credentialed-supervise across a regional lab network is meaningfully higher than a single-clinic HCLD. That is itself a multi-clinic platform advantage.

The Terra Fertility spin-out of three Boston IVF REIs in September 2025 is the explicit warning signal on REI retention (Fertility Bridge). Industry chatter places multiple other potential spin-out conversations across Inception, Pinnacle, and CCRM. The non-compete enforcement question varies by state: California voids non-competes by statute, so any California REI under PE platform employment can spin out with limited contractual friction; Texas, Florida, and New York enforce non-competes more strictly. The non-compete map therefore disproportionately exposes California-heavy platforms to physician attrition risk.

Compensation benchmarking is itself becoming a competitive lever. MGMA’s specialty-level data on REI compensation, the SREI member survey, and Fertility Bridge’s anonymized network surveys are the three reference points. The gap between the most-cited 2021 MGMA figure ($461,997) and the March 2026 Fertility Bridge starting-comp range ($650,000 base plus bonuses in lower-supply markets) is wide enough that platforms relying on outdated MGMA benchmarks are under-paying recruits and bleeding to spin-outs (Fertility Bridge). Diligence on platform acquisitions should request current compensation benchmarks by site, not network-blended numbers.

15. FTC, HIPAA, and the Data Handling Cost Base

The FTC has yet to bring a published action against a fertility MSO for advertising or success-rate disclosure violations, but the FTC’s broader Health Breach Notification Rule expansion (effective 2024) and the HHS Office for Civil Rights April 22, 2024 Final Rule on reproductive health protected health information both increase the data-handling cost base for any fertility platform. Embryo-personhood litigation in any other state would by itself create cross-jurisdictional risk for multi-state platforms. LePage applied only to Alabama, but a similar ruling in Texas or Florida would directly affect IVI RMA, Pinnacle, and US Fertility. Diligence should price in cyber-insurance premium increases and a step-change in compliance staffing at the platform level.

The HHS reproductive health PHI rule, effective December 23, 2024 for most provisions, restricts use and disclosure of reproductive PHI for purposes of conducting a criminal, civil, or administrative investigation against any person for the mere act of seeking, obtaining, providing, or facilitating reproductive health care. Fertility clinics that operate in multiple states, including states with restrictive reproductive policies, now face an attestation requirement before responding to PHI requests in litigation. Compliance staffing implications hit the platforms with the largest multi-state footprints hardest: US Fertility’s 20-state coverage, IVI RMA’s six US states plus Boston IVF New England, and Pinnacle’s 40+ clinics across 13+ states each require updated business associate agreements, attestation workflows, and counsel review on every PHI request.

The FTC Health Breach Notification Rule expansion captured health apps and ancillary digital fertility products that were previously outside its scope. Period-tracking apps and fertility-tracking apps now fall inside the rule. The implication for fertility benefits managers (Progyny, Carrot, Maven) is that any digital health partner integration carries cleanup costs that did not exist before 2024. Diligence on benefits managers should examine the third-party app stack with the same rigor that diligence on clinic platforms examines lab software.

SART success rate reporting is another diligence axis. SART CORS publishes per-clinic outcomes through a public-facing dashboard, and Bloomberg’s “IVF Disrupted” coverage flagged the Kindbody success rate question in 2024 (Sacra Kindbody). Clinic-level success rate variation is partly driven by case mix (older patients, donor-egg cycles, second-time cycles), but it is also driven by lab quality and embryologist skill. Multi-clinic platforms can mask weak clinics inside aggregate network averages; standalone clinics cannot. Diligence on platform acquisitions should request site-by-site success rate data from the SART CORS reporting line rather than relying on aggregate marketing claims.

16. Seller Fit Matrix: Who Should Sell to Whom

The matrix below maps clinic-owner archetypes to the most natural buyer set, given the 2024 to 2026 sponsor profile. This is intended as a starting point for clinic owners considering a sale and is not transactional advice.

This matrix is intentionally narrower than the full universe. Clinic owners who think their practice fits multiple archetypes should treat the table as a starting point for a banker conversation, not a recommendation. CT Acquisitions’s how-to-sell-a-fertility-clinic guide covers the broader process.

For founder-physicians considering a sale, three operational variables shape the multiple beyond pure EBITDA scale. First, REI bench depth: a clinic with two REIs commands a higher multiple than a clinic dependent on a single REI for cycle production. Buyers price single-physician concentration risk explicitly. Second, embryology lab quality: a clinic with its own CLIA-certified high-complexity lab and an HCLD or ELD on staff has more multiple support than a clinic that outsources embryology. Third, payor mix: a clinic with 50 percent or more commercial-payor coverage carries less near-term mandate-transition risk than a clinic with 90 percent cash-pay. Buyers running California or Massachusetts diligence weight payor mix heavily; buyers running Texas or Florida diligence weight cash-pay pricing power heavily.

The window for above-trend multiples is plausibly 2026 to 2027. Three exits (Inception, Pinnacle, Kindbody) are anticipated and would re-rate the sector. A favorable Inception or Pinnacle exit at the upper end of the 10x to 12x band would pull comparable transactions up; an unfavorable exit at the lower end would pull comparable transactions down. Sellers should track those three clearance events closely. CT Acquisitions’s sell-side guide covers the timing-to-market question in operational detail.

17. Limitations of This Tracker

Three limitations are worth flagging up front. First, the CDC NASS lag is 24 to 36 months, so the 2022 reporting year is the most recent federally audited dataset available as of June 16, 2026 (CDC NASS). 2023 numbers from SART CORS are reliable for outcome data but do not have the same audit assurance as the CDC release. Second, EBITDA multiples cited from PitchBook are sector benchmarks rather than transaction multiples; specific deal multiples for the named transactions (USF/L Catterton, IVI RMA/Eugin, Unified/CCRM, KKR/IVI RMA) are not disclosed in press releases beyond aggregate enterprise value. Third, the universe of small single-clinic acquisitions below the disclosure threshold is materially larger than the named-deal universe, and that long tail is captured only intermittently in PitchBook and Fertility Bridge.

The platforms covered here are those with verifiable 2024 to 2026 ownership in primary sources. Smaller independent operators, regional networks below the platform-acquisition threshold, and single-clinic groups are excluded except where they appear as targets of named transactions. Donor-egg brokerages, sperm banks, and fertility software companies are covered only where they are explicitly part of a tracked PE platform’s vertical.

Where the original briefing material cited a sponsor that could not be verified in primary sources, the attribution is moved to Section 19 with the verified replacement in the platform row. This is the same gating that the sibling trackers for home health, behavioral health, ABA, veterinary, dermatology, dental DSO, physical therapy, ophthalmology, gastroenterology, and orthopedic care have applied.

A fourth limitation is that the sector classification of certain hybrid platforms (Kindbody, Maven) sits on a spectrum between clinic operator and benefits manager. Where a platform straddles those categories, the tracker assigns the platform to the segment that captures the larger share of revenue per the most recent disclosed financials. Kindbody is classified primarily as a clinic-plus-benefits hybrid because the owned clinic network drives the majority of operating cycle volume; Maven is classified primarily as a benefits manager because the women’s-and-family-benefits product suite drives the majority of disclosed revenue. Those classifications may shift in future tracker revisions if either platform pivots more aggressively toward one side.

A fifth limitation is currency. Cross-border transactions involving Eugin (Spain), Jinxin (Hong Kong), and ART Fertility Clinics (Middle East and India) are translated to US dollars at the announcement-date exchange rate where available. The actual closing-date exchange rate may differ. Reported deal values for cross-border transactions therefore carry an approximate-equivalent footnote in the underlying source material.

18. Related CT Acquisitions Research

This tracker is the latest in a sibling series across healthcare verticals. Each tracker uses the same cap-table verification methodology and primary-source citation gating.

• CT Acquisitions PE Platform Map (master cross-vertical index)
• Home Health PE Roll-Up Tracker (sibling)
• Behavioral Health PE Roll-Up Tracker (sibling)
• ABA Therapy PE Roll-Up Tracker (sibling)
• Veterinary PE Roll-Up Tracker (sibling)
• Dermatology PE Roll-Up Tracker (sibling)
• Dental DSO PE Roll-Up Tracker (sibling)
• Physical Therapy PE Roll-Up Tracker (sibling)
• Ophthalmology PE Roll-Up Tracker (sibling)
• Gastroenterology PE Roll-Up Tracker (sibling)
• Orthopedic PE Roll-Up Tracker (sibling)
• How to Sell a Fertility Clinic (operational sell-side guide)

19. Gap Disclosures: Unverified Items

The following items either appeared in older briefing material that could not be verified against 2024 to 2026 primary sources, or surfaced as rumors that we could not independently verify. They are flagged here so that future tracker revisions can either confirm or retire each item.

1. Inception Fertility + MSD Capital: MSD Capital / DFO Management ownership of Inception Fertility cannot be verified in any 2024 to 2026 primary source. Lee Equity Partners is the verifiable majority sponsor (Axios). Treat MSD Capital reference as legacy or unverified.
2. US Fertility + Lee Equity Partners: Cannot be verified. USF’s actual cap table is Amulet Capital plus L Catterton (December 30, 2025) plus physician owners (Fertility Bridge).
3. US Fertility + Optum: Rumor only. No primary source confirmation as of June 2026. Modeled as a 12 to 24 month strategic exit possibility in Section 13 Finding 4.
4. Pinnacle Fertility + Welsh Carson Anderson and Stowe (WCAS): Incorrect. Webster Equity Partners is the sole institutional sponsor per Webster’s own portfolio page (Webster portfolio). WCAS’s 2024 to 2025 healthcare activity was AssistRx and Constitution Surgery Alliance, not Pinnacle (Tracxn WCAS).
5. CCRM + Patricia Industries: Cannot be verified. Unified Women’s Healthcare (Altas Partners plus Ares Management PE plus Oak HC/FT) owns CCRM since September 10, 2023 (World IVF Life Sciences). TA Associates was a prior CCRM sponsor (TA Associates).
6. Fertility Centers of Illinois (FCI) under Pinnacle: Not in any Pinnacle press release. Pinnacle’s Illinois assets are Institute for Human Reproduction (Chicago), IVF1 (Naperville), and Center for Reproductive Care (Chicago). FCI remains separately operated per ZoomInfo (ZoomInfo FCI).
7. FOCUS / Provident / Mertz Taggart fertility-specific quarterly reports: None published with fertility-vertical granularity comparable to Mertz Taggart’s home-based-care series. PitchBook’s Q2 2024 Healthcare Services Report and Fertility Bridge are the only consistent quarterly trackers identified.
8. 2023 and 2024 CDC NASS releases: Only 2022 reporting year is currently published on the CDC dashboard as of June 16, 2026 (CDC NASS). 2023 data appears in SART CORS but not yet in CDC NASS. CDC NASS lag is roughly 24 to 36 months.
9. Embryologist count nationwide: No published BLS or ABB count of US embryologists. ABB publishes certification counts internally but not as an annual public report.
10. Specific Progyny acquisition target names 2024 to 2025: Progyny’s 10-Q filings disclose $5.3 million Q3 2024 and $9.3 million Q2 2025 of “acquisition of businesses” cash spend but do not name targets (Progyny 10-K). Smaller-than-disclosure-threshold tuck-ins.

20. Sources (Master List)

• CDC ART Surveillance: cdc.gov/art/php/surveillance
• CDC NASS state dashboard: cdc.gov/art/php/nass
• CDC 2021 ART summary: stacks.cdc.gov/view/cdc/154438
• SART CORS multi-year summary: sartcorsonline.com
• SART 2023 outcome tables: SART outcomes
• Contemporary OB/GYN on 2022 SART growth: contemporaryobgyn.net
• Bhargava et al, Fertility and Sterility 2025: fertstert.org
• MedicalXpress summary of PE share study: medicalxpress.com
• Rewire News on PE growth: rewirenewsgroup.com
• ASRM 2025 REI subspecialist definition: asrm.org
• Fertility Bridge tracking 2024 REI fellows: fertilitybridge.com
• Fertility Bridge fertility center networks 2026: fertilitybridge.com
• Fertility and Sterility REI in 2035: fertstert.org
• Fertility and Sterility REI fellowship funding model: fertstert.org
• BLS Physicians and Surgeons OOH: bls.gov
• ABB (American Board of Bioanalysis): aab.org
• LePage v. Center for Reproductive Medicine (Justia): law.justia.com
• Goodwin Law on LePage: goodwinlaw.com
• ASRM on LePage: asrm.org
• Alabama SB159: healthlawadvisor.com
• Cornell JLPP on fetal personhood: cornell.edu
• MultiState 2025 fertility legislation: multistate.us
• Fertility Bridge legislation trends: fertilitybridge.com
• Duckworth Right to IVF Act: duckworth.senate.gov
• Duckworth FEHB IVF expansion: duckworth.senate.gov
• Trump February 2025 EO (AJMC): ajmc.com
• White House fact sheet October 2025: whitehouse.gov
• RESOLVE state mandate map: resolve.org
• Sequoia on California SB 729: sequoia.com
• Mercer 2024 employer benefits: mercer.com
• Mercer 2025 maintenance: mercer.com
• US Fertility / L Catterton (Fertility Bridge): fertilitybridge.com
• US Fertility / L Catterton (Amulet press): amuletcapital.com
• US Fertility / L Catterton (Harris Williams): harriswilliams.com
• US Fertility / L Catterton (Moelis): moelis.com
• US Fertility original Amulet formation: businesswire.com
• Morgan Stanley / Ovation sale to USF: morganstanley.com
• KKR / IVI-RMA acquisition (Jones Day): jonesday.com
• IVI RMA Eugin / Boston IVF close: businesswire.com
• IVI RMA Eugin commentary: healthcarebusinessinternational.com
• IVI RMA Southern California 2025 add-ons: privsource.com
• Lee Equity launches Prelude: prnewswire.com
• Axios on Lee Equity seeking Inception buyer: axios.com
• Prelude / Sincera Philadelphia 2023: prnewswire.com
• Prelude / Reproductive Science Center NJ 2024: finance.yahoo.com
• Webster Equity Partners portfolio (Pinnacle): websterequitypartners.com
• Pinnacle / California Fertility Partners: bnco.com
• Pinnacle / IVF1: privsource.com
• Pinnacle / Institute for Human Reproduction: privsource.com
• Pinnacle PitchBook profile: pitchbook.com
• Unified Women’s Healthcare / CCRM $775M: worldivflifesciencesbusiness.com
• Unified / CCRM 2021 strategic partnership: businesswire.com
• TA Associates CCRM page: ta.com
• CCRM acquires RADfertility: ccrmivf.com
• Kindbody / Perceptive $100M: prnewswire.com
• Sacra Kindbody profile: sacra.com
• Spring Fertility / Wildcat: springfertility.com
• Progyny Q4 2025 results: investors.progyny.com
• Progyny 10-K (FY24 annual): investors.progyny.com
• Carrot 4,200 providers August 2025: get-carrot.com
• Maven Clinic Wikipedia: en.wikipedia.org
• Fertility Bridge 2025 M&A pipeline: fertilitybridge.com
• PitchBook on ancillary services thesis Q2 2024: pitchbook.com
• PMC literature review on PE in fertility: pmc.ncbi.nlm.nih.gov
• Fertility Bridge 2024 ownership list: fertilitybridge.com
• AmboyStreet on Eugin $535M: amboystreet.vc
• Tracxn WCAS acquisitions: tracxn.com
• ZoomInfo Fertility Centers of Illinois: zoominfo.com
• Pinnacle Fertility press page: pinnaclefertility.com
• Tracxn Kindbody profile: tracxn.com
• PitchBook Inception profile: pitchbook.com

21. Frequently Asked Questions

Who actually owns Pinnacle Fertility?

Pinnacle Fertility’s sole institutional sponsor is Webster Equity Partners. Webster’s own portfolio page lists Pinnacle (Webster portfolio). The Welsh Carson Anderson and Stowe attribution in some older summaries is incorrect; WCAS’s 2024 to 2025 healthcare activity went into AssistRx and Constitution Surgery Alliance, not Pinnacle (Tracxn WCAS).

Who owns CCRM Fertility today, and is Patricia Industries involved?

CCRM has been owned by Unified Women’s Healthcare since September 10, 2023, when Unified bought CCRM for $775 million (World IVF Life Sciences Business). Unified is backed by Altas Partners, the Private Equity Group of Ares Management Corporation, and Oak HC/FT (Unified press). The Patricia Industries reference cannot be verified in 2024 to 2026 primary sources. TA Associates was a prior CCRM sponsor (TA Associates).

Who recapitalized US Fertility in December 2025?

L Catterton joined Amulet Capital Partners as co-lead sponsor of US Fertility on December 30, 2025 (Fertility Bridge). The financing structure was an $825 million first-lien term loan B due 2032 plus $1.71 billion of new cash and rollover equity. Lee Equity is not in the US Fertility cap table. Moelis advised USF and Amulet (Moelis); Harris Williams advised L Catterton (Harris Williams).

What did the Alabama LePage ruling do to the IVF industry?

On February 16, 2024, the Alabama Supreme Court held that frozen embryos qualify as children under Alabama’s Wrongful Death of a Minor Act (Justia LePage). Three Alabama IVF clinics suspended embryo transfer or storage operations during a three-week window before the Alabama Legislature passed SB159 on March 7, 2024, granting civil and criminal immunity to entities for embryo damage in connection with IVF (Health Law Advisor). Sixteen states subsequently introduced 40+ fetal-personhood bills in 2024 (Cornell JLPP); Tennessee, Georgia, Louisiana, Nevada, and Colorado have passed protective statutes.

When does California SB 729 take effect?

California SB 729 takes effect January 1, 2026 for fully-insured large-group plans and July 1, 2026 for state-employee plans, after two prior delays from the original July 1, 2025 trigger (Sequoia SB 729). It is the single largest 2026 catalyst because California accounts for an estimated 18 to 20 percent of US ART cycles, and the bill converts the majority of fully-insured large-group California demand from cash-pay to mandate-paid.

What percentage of US IVF cycles are performed at PE-affiliated clinics?

Per Bhargava et al in Fertility and Sterility December 2025, by end of 2023, 163 of approximately 508 SART-member clinics (32.1 percent) were PE-affiliated, and those clinics performed 54.0 percent of all IVF cycles nationally, up from 13.3 percent in 2013 (Bhargava et al). In 14 states plus DC, half or more of all fertility clinics are PE-affiliated.

How many REIs are there in the US?

ASRM’s 2025 subspecialist scope document cites roughly 1,300 board-certified REIs nationally, with about 60 new fellows entering the workforce each year (ASRM 2025). The 2024 REI fellowship class produced 60 fellows from 53 programs (Fertility Bridge).

What multiples are PE buyers paying for fertility platforms in 2026?

Per PitchBook Q2 2024, add-on and minority investments clear at 7x to 9x adjusted EBITDA, platform transactions at 10x to 12x EBITDA, smaller clinic groups ($2 to $5 million EBITDA) at 7x to 9x EBITDA, and larger fertility groups ($10 million plus EBITDA) at double-digit multiples (PitchBook). Named platform reference points include Unified paying $775 million for CCRM in September 2023 and KKR paying roughly $3.2 billion for IVI-RMA Global in 2022.

Is Progyny a clinic operator?

No. Progyny is a publicly traded fertility benefit manager (NASDAQ: PGNY), not a clinic operator. Progyny earned $1,288.7 million of 2025 revenue and guides to approximately 600 clients and 7.2 million members in 2026 (Progyny Q4 2025). Progyny’s main competitors on the benefits side are Carrot Fertility (private VC) and Maven Clinic (private VC).

How fast are REI starting salaries rising?

Fertility Bridge reports incoming REI starting salaries in lower-supply markets reached $650,000 base plus bonuses in March 2026, up from a $400,000 average reported in a January 2020 SREI member survey (Fertility Bridge trends). That is approximately a 60 percent increase in starting comp over five years.

What is the Terra Fertility spin-out?

Three Boston IVF REIs departed in September 2025 to launch Terra Fertility as an independent practice (Fertility Bridge). It is the first documented physician spin-out from a KKR-owned clinic post-Eugin close and is being watched as a leading indicator for the broader REI retention thesis at PE-owned clinic networks.

When did CLIA’s high-complexity director rule change?

CLIA updates to high-complexity director regulations took effect December 28, 2024, raising the credential bar for embryology laboratory directors (ABB). This effectively constrained the embryologist supply pool further and concentrated bargaining power inside larger lab networks such as Ovation (now within US Fertility) and the CCRM lab system.

22. About This Tracker

This tracker is part of the CT Acquisitions PE Roll-Up Tracker series, which covers healthcare verticals where PE consolidation has been measurable. The series is researched and maintained by the CT Acquisitions research team using primary-source verification: sponsor portfolio pages, SEC filings, named press releases, PitchBook profiles, peer-reviewed studies, and federal statistical releases. Cross-vertical sibling trackers are linked in Section 18.

CT Acquisitions advises sellers and buyers on healthcare service M&A across the United States. The firm does not represent any of the sponsors listed in this tracker and has no fiduciary relationship with any platform mentioned. This tracker is for informational purposes only and should not be construed as transactional advice. For sell-side guidance specific to fertility clinics, see How to Sell a Fertility Clinic.

Methodology note for cross-tracker comparison: the CT Acquisitions PE roll-up tracker series uses the same cap-table verification rules across every vertical. For each tracker, sponsor names are verified against sponsor portfolio pages, SEC filings, named press releases, PitchBook profiles, peer-reviewed studies, and federal statistical releases. Where a sponsor name surfaces only in older secondary press without primary-source confirmation, the attribution is moved to the Gap Disclosures section and the platform row uses the verified replacement. This is the same rule that surfaced corrected sponsor attributions for the home health, behavioral health, ABA, veterinary, dermatology, dental DSO, physical therapy, ophthalmology, gastroenterology, and orthopedic trackers in this series. Reader feedback and corrections are welcome at the CT Acquisitions site.

Update cadence: this tracker is reviewed quarterly and rebaselined when a named platform sponsor transaction closes. Mid-quarter updates may be issued when material regulatory or judicial events affect the sector (an analogous LePage-style ruling, a federal Right to IVF Act re-introduction with a different floor outcome, or a payor-to-clinic strategic acquisition that materially re-rates the comparable multiples). Readers tracking specific platforms should also monitor sponsor portfolio pages, SEC filings for any publicly affiliated entities, and the SART CORS dashboard for per-clinic success rate updates that may signal operational issues at platform sites.

One specific event we are watching for the next tracker revision: a payor-to-clinic platform acquisition by Optum, Aetna, or Evernorth as discussed in Section 13 Finding 4. If such a transaction clears in the 2026 to 2027 window, the comparable transaction multiples will reset upward and the contrarian view expressed here will move to the central case. Readers should also watch for any signal of a Texas or Florida state supreme court decision analogous to LePage, which would compress comparable transaction multiples temporarily and reshape platform-level diligence. Both of those events would warrant a mid-cycle tracker update.

Last updated: June 16, 2026. Next scheduled review: September 2026 or upon next named sponsor transaction.